Insider sale details
Viatris Inc. (NASDAQ: VTRS) reported that Paul Campbell, the company's Chief Accounting Officer and Corporate Controller, sold 21,350 shares of common stock on March 23, 2026, per a Form 4 filing with the Securities and Exchange Commission. The shares were disposed of at a weighted average price of $13.2805, producing total proceeds of $283,538. Reported sale prices ranged from $13.205 to $13.34.
Holding after the sale
Following the transaction, Campbell directly holds 366,288 shares of Viatris Inc. In addition, he is recorded as indirectly owning 318 shares through a 401(k) Plan.
Stock performance and valuation context
The transaction took place as the stock had declined 3.19% over the prior week, while remaining about 40% higher over the preceding six months. According to InvestingPro analysis cited in the filing data, Viatris had a Fair Value estimate of $15.43 compared with a reported current trading price of $13.35. The company was described as carrying a market valuation of $15.4 billion and offering a dividend yield of 3.59%.
Company outlook and regulatory development
Viatris has published multi-year financial targets through 2030. The company projects combined annual revenue growth of 5% to 6% through 2030. Over the same period, management expects adjusted EBITDA to increase by 7% to 8% annually and adjusted earnings per share to grow by 9% to 10% annually. Viatris also forecasts its annual free cash flow to exceed $3 billion by 2030.
On the regulatory front, Viatris disclosed that Japan's Ministry of Health, Labour and Welfare approved Effexor SR capsules for the treatment of generalized anxiety disorder in adults, which the company described as the first approved treatment option for this indication in Japan.
Analyst reactions
Several brokerage firms adjusted their price targets for Viatris following the company's recent updates. Barclays raised its price target to $17.00 from $15.00 and kept an Overweight rating, citing the company's pipeline potential while noting lower expectations for EBITDA growth. UBS increased its target to $20 from $18 and retained a Buy rating after Viatris met anticipated cost-saving targets discussed on the fourth-quarter 2025 earnings call. BofA Securities raised its price target to $12.00 from $10.00 but kept an Underperform rating, following fourth-quarter results that exceeded sales and EBITDA expectations by approximately 5%.
Implications and context
The Form 4 filing documents a sizable sale by a senior financial officer but shows that Campbell continues to hold a substantial position in the company. The disclosure of 2030 financial targets, the Japanese regulatory approval for Effexor SR, and multiple analyst price-target revisions were also highlighted in the filings and public statements referenced in the company's communications.
Readers should note that the numbers and guidance above are taken from the company's disclosures and associated analyst notes referenced in the public filing. The filing specifies the transaction details and the holdings reported after the sale.